ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the tr…
Biotechnology
US, San Diego [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about ACADIA Pharmaceuticals Inc.'s gradings, price targets and earnings estimates.
Earnings
See the historical earnings and what wall street
analysts forecasted and
forecast for
future earnings.
Reported
Past Estimate Consensus
Future Estimate Consensus
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2014 | -0.4400 | -0.665 | 1 | 0.10 | -37 | -76 | -38 | -76 | -38 | -76 | 12 | 0.08 |
| 2015 | -0.9500 | -1.583 | 0.12 | 0.97 | -92 | -132 | -93 | -131 | -93 | -132 | 32 | 0.76 |
| 2016 | -1.6300 | -2.342 | 0.06 | 14 | -164 | -241 | -164 | -238 | -164 | -242 | 90 | 11 |
| 2017 | -2.3400 | -2.397 | 17 | 126 | -271 | -319 | -272 | -316 | -272 | -322 | 186 | 99 |
| 2018 | -2.3600 | -1.991 | 124 | 223 | -289 | -262 | -292 | -257 | -292 | -264 | 255 | 175 |
| 2019 | -1.9400 | -1.618 | 223 | 337 | -245 | -246 | -247 | -239 | -247 | -259 | 265 | 265 |
| 2020 | -1.6000 | -1.840 | 339 | 443 | -235 | -257 | -246 | -247 | -246 | -262 | 325 | 385 |
| 2021 | -1.7900 | -1.019 | 441 | 487 | -281 | -187 | -286 | -182 | -286 | -190 | 388 | 455 |
| 2022 | -1.0500 | -1.315 | 484 | 514 | -167 | -252 | -170 | -246 | -170 | -254 | 396 | 466 |
| 2023 | -1.3400 | -0.358 | 517 | 719 | -215 | -61 | -223 | -271 | -223 | -280 | 369 | 512 |
| 2024 | - | 0.541 | - | 952 | - | 88 | - | -429 | - | -435 | - | 747 |
| 2025 | - | 0.821 | - | 1,055 | - | 150 | - | -475 | - | -482 | - | 828 |
| 2026 | - | 1.322 | - | 1,176 | - | 2.F12X/td> | - | 2.F121/td> | - | 2.F121 | - | 2.F121 |
| 2027 | - | 1.882 | - | 1,296 | - | 1.F13X/td> | - | 1.F131/td> | - | 1.F131 | - | 1.F131 |
| 2028 | - | 2.324 | - | 1,420 | - | 0.F14X/td> | - | 0.F141/td> | - | 0.F141 | - | 0.F141 |
Institutional Sentiment
Wall Street · Earnings · Institutional Sentiment
Morgan Stanley
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
JP Morgan Chase
1Y Ago:
Overweight
Prev. Grade
Equal-Weight
Nov. 6, 2024
Overweight
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the gradePrice Target Consensus
-54.429% $8.91 · MISS
Nov. 6, 2024Price Then
$15.00
Price Target
$25.28
Price Now
$16.37